403 related articles for article (PubMed ID: 19366842)
21. Ovarian responses in women to recombinant follicle-stimulating hormone and luteinizing hormone (LH): a role for LH in the final stages of follicular maturation.
Sullivan MW; Stewart-Akers A; Krasnow JS; Berga SL; Zeleznik AJ
J Clin Endocrinol Metab; 1999 Jan; 84(1):228-32. PubMed ID: 9920089
[TBL] [Abstract][Full Text] [Related]
22. Endocrine response determines the clinical outcome of pulsatile gonadotropin-releasing hormone ovulation induction in different ovulatory disorders.
Filicori M; Flamigni C; Meriggiola MC; Ferrari P; Michelacci L; Campaniello E; Valdiserri A; Cognigni G
J Clin Endocrinol Metab; 1991 May; 72(5):965-72. PubMed ID: 1902487
[TBL] [Abstract][Full Text] [Related]
23. Ovulation induction in clomiphene-resistant anovulatory women: differential follicular response to purified urinary follicle-stimulating hormone (FSH) versus purified urinary FSH and luteinizing hormone.
Hoffman DI; Lobo RA; Campeau JD; Tsai HM; Holmberg EA; Ono T; Frederick JJ; Platt LD; diZerega GS
J Clin Endocrinol Metab; 1985 May; 60(5):922-7. PubMed ID: 3920235
[TBL] [Abstract][Full Text] [Related]
24. Luteinizing hormone activity supplementation enhances follicle-stimulating hormone efficacy and improves ovulation induction outcome.
Filicori M; Cognigni GE; Taraborrelli S; Spettoli D; Ciampaglia W; de Fatis CT; Pocognoli P
J Clin Endocrinol Metab; 1999 Aug; 84(8):2659-63. PubMed ID: 10443656
[TBL] [Abstract][Full Text] [Related]
25. Recombinant human LH supplementation versus recombinant human FSH (rFSH) step-up protocol during controlled ovarian stimulation in normogonadotrophic women with initial inadequate ovarian response to rFSH. A multicentre, prospective, randomized controlled trial.
De Placido G; Alviggi C; Perino A; Strina I; Lisi F; Fasolino A; De Palo R; Ranieri A; Colacurci N; Mollo A;
Hum Reprod; 2005 Feb; 20(2):390-6. PubMed ID: 15576390
[TBL] [Abstract][Full Text] [Related]
26. The effect of exogenous luteinizing hormone (LH) on oocyte viability: evidence from a comparative study using recombinant human follicle-stimulating hormone (FSH) alone or in combination with recombinant LH for ovarian stimulation in pituitary-suppressed women undergoing assisted reproduction.
Balasch J; Creus M; Fábregues F; Civico S; Carmona F; Puerto B; Casamitjana R; Vanrell JA
J Assist Reprod Genet; 2001 May; 18(5):250-6. PubMed ID: 11464575
[TBL] [Abstract][Full Text] [Related]
27. Hypogonadotropic patients with ultrasonographically detected polycystic ovaries: endocrine response to pulsatile gonadotropin-releasing hormone.
Schachter M; Balen AH; Patel A; Jacobs HS
Gynecol Endocrinol; 1996 Oct; 10(5):327-35. PubMed ID: 8915662
[TBL] [Abstract][Full Text] [Related]
28. Induction of multiple follicular development by a single dose of long-acting recombinant follicle-Stimulating hormone (FSH-CTP, corifollitropin alfa) for controlled ovarian stimulation before in vitro fertilization.
Devroey P; Fauser BC; Platteau P; Beckers NG; Dhont M; Mannaerts BM
J Clin Endocrinol Metab; 2004 May; 89(5):2062-70. PubMed ID: 15126522
[TBL] [Abstract][Full Text] [Related]
29. Different follicle stimulating hormone/luteinizing hormone ratios for ovarian stimulation.
Duijkers IJ; Vemer HM; Hollanders JM; Willemsen WN; Bastiaans LA; Hamilton CJ; Thomas CM; Borm GF
Hum Reprod; 1993 Sep; 8(9):1387-91. PubMed ID: 8253923
[TBL] [Abstract][Full Text] [Related]
30. Gonadotropin-releasing hormone (GnRH) analog suppression renders polycystic ovarian disease patients more susceptible to ovulation induction with pulsatile GnRH.
Filicori M; Campaniello E; Michelacci L; Pareschi A; Ferrari P; Bolelli G; Flamigni C
J Clin Endocrinol Metab; 1988 Feb; 66(2):327-33. PubMed ID: 3123511
[TBL] [Abstract][Full Text] [Related]
31. Differentiation of male hypogonadotropic hypogonadism and constitutional delay of puberty by pulsatile administration of gonadotropin-releasing hormone.
Partsch CJ; Hermanussen M; Sippell WG
J Clin Endocrinol Metab; 1985 Jun; 60(6):1196-203. PubMed ID: 3923024
[TBL] [Abstract][Full Text] [Related]
32. Ovulation induction with low doses of "pure" follicle stimulating hormone using a fixed protocol in patients with polycystic ovarian disease.
Bregieiro LO; de Moura MD; Ferriani RA; Bailão LA; de Sá MF
Int J Fertil Menopausal Stud; 1993; 38(3):152-9. PubMed ID: 8348163
[TBL] [Abstract][Full Text] [Related]
33. Does gonadotropin suppression result in follicular development in premature ovarian failure?
Buckler HM; Healy DL; Burger HG
Gynecol Endocrinol; 1993 Jun; 7(2):123-8. PubMed ID: 8213226
[TBL] [Abstract][Full Text] [Related]
34. Twin pregnancy using recombinant gonadotropins in a woman with hypogonadotropic hypogonadism.
Campo S; Campo V; Lanzone A
Gynecol Endocrinol; 2002 Feb; 16(1):27-32. PubMed ID: 11915578
[TBL] [Abstract][Full Text] [Related]
35. Recovery of hormone secretion after chronic gonadotropin-releasing hormone agonist administration in women with polycystic ovarian disease.
de Ziegler D; Steingold K; Cedars M; Lu JK; Meldrum DR; Judd HL; Chang RJ
J Clin Endocrinol Metab; 1989 Jun; 68(6):1111-7. PubMed ID: 2524501
[TBL] [Abstract][Full Text] [Related]
36. The clinical therapeutic window for luteinizing hormone in controlled ovarian stimulation.
Shoham Z
Fertil Steril; 2002 Jun; 77(6):1170-7. PubMed ID: 12057724
[TBL] [Abstract][Full Text] [Related]
37. Low-dose exogenous FSH initiated during the early, mid or late follicular phase can induce multiple dominant follicle development.
Hohmann FP; Laven JS; de Jong FH; Eijkemans MJ; Fauser BC
Hum Reprod; 2001 May; 16(5):846-54. PubMed ID: 11331627
[TBL] [Abstract][Full Text] [Related]
38. Regulation of vascular endothelial growth factor-A and its soluble receptor sFlt-1 by luteinizing hormone in vivo: implication for ovarian follicle angiogenesis.
Gutman G; Barak V; Maslovitz S; Amit A; Lessing JB; Geva E
Fertil Steril; 2008 Apr; 89(4):922-6. PubMed ID: 18343373
[TBL] [Abstract][Full Text] [Related]
39. Follicular fluid hormonal profile and cumulus cell gene expression in controlled ovarian hyperstimulation with recombinant FSH: effects of recombinant LH administration.
Barberi M; Ermini B; Morelli MB; Ermini M; Cecconi S; Canipari R
J Assist Reprod Genet; 2012 Dec; 29(12):1381-91. PubMed ID: 23188412
[TBL] [Abstract][Full Text] [Related]
40. The role of endogenous gonadotropin release in the etiology of ovarian enlargement during purified urinary follicle-stimulating hormone therapy.
Mizunuma H; Takagi T; Yamada K; Andoh K; Ibuki Y; Igarashi M
Fertil Steril; 1991 Jan; 55(1):66-72. PubMed ID: 1898893
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
